Illumina, Inc. $ILMN is Spyglass Capital Management LLC’s 9th Largest Position

Spyglass Capital Management LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 41.1% in the second quarter, HoldingsChannel reports. The firm owned 458,767 shares of the life sciences company’s stock after acquiring an additional 133,718 shares during the period. Illumina accounts for about 4.4% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 9th biggest holding. Spyglass Capital Management LLC’s holdings in Illumina were worth $80,665,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Illumina in the second quarter valued at $3,374,423,000. Plato Investment Management Ltd purchased a new position in shares of Illumina during the second quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Illumina during the second quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new position in Illumina during the second quarter valued at $129,792,000. Finally, Impact Partnership Wealth LLC lifted its stake in Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after acquiring an additional 7,780 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider owned 20,338 shares in the company, valued at $4,067,600. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,799,688 shares of company stock worth $379,517,231 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $213.63 on Tuesday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81. The stock’s 50-day moving average is $195.10 and its two-hundred day moving average is $156.54. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $32.26 billion, a P/E ratio of 39.86, a PEG ratio of 3.03 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their target price on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Royal Bank Of Canada raised their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. TD Cowen boosted their price objective on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.